YCBD
cbdMD, Inc.
YCBD lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
YCBD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Strong |
YCBD's revenue and balance sheet are currently healthy, but its profitability and cash flow are weak.
YCBD PE Valuation
YCBD has no meaningful PE right now: it lost money over the past year.
YCBD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect YCBD's losses to shrink, with revenue growing.
YCBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$71.92 | +$66.48 |
| Q1 2024 | -$80.00 | +$247.12 |
| Q4 2023 | -$83.12 | +$266.08 |
| Q3 2023 | -$106.56 | +$339.84 |
| Q2 2023 | -$138.40 | +$246.80 |
| Q1 2023 | -$327.12 | -$147.12 |
| Q4 2022 | -$349.20 | -$118.80 |
| Q3 2022 | -$446.40 | -$277.20 |
YCBD lost $0.40 per share over the past year, a smaller loss than the year before.
YCBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.6M | +21% |
| Q1 2026 | $5.6M | +19% |
| Q4 2025 | $5M | -1.9% |
| Q3 2025 | $4.7M | +3.6% |
| Q2 2025 | $4.6M | -11% |
| Q1 2025 | $4.7M | +8.5% |
| Q4 2024 | $5.1M | -4.9% |
| Q3 2024 | $4.6M | -20% |
YCBD's revenue is recovering but still below its 2020 peak: $6M last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -20% | -0.7 points |
| Q1 2026 | -14% | -4 points |
| Q4 2025 | -5.7% | -4 points |
| Q3 2025 | -15% | -7.6 points |
| Q2 2025 | -20% | -12 points |
| Q1 2025 | -10% | +25 points |
| Q4 2024 | -1.7% | +18 points |
| Q3 2024 | -7% | +260 points |
YCBD's operating margin was −20% last quarter, down 0.7 points from the same quarter a year ago.
YCBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$460.2K | +$245.5K |
| Q3 2025 | -$243.6K | -255% |
| Q2 2025 | -$705.7K | -344% |
| Q3 2024 | $157.4K | +$541.1K |
| Q2 2024 | $289.8K | +$632.7K |
| Q1 2024 | -$699.4K | +$931.8K |
| Q4 2023 | -$290.5K | +$2M |
| Q3 2023 | -$383.7K | +$1.8M |
YCBD has burned cash in most quarters: −$2M over the past year, against −$957,967 the year before.
YCBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +173K shares |
| 1 year | +1264% | +9.8M shares |
| 3 years | +6297% | +10.5M shares |
| 5 years | +10137% | +10.5M shares |
YCBD has 11M diluted shares, up 1264% from a year ago.
YCBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | -0.4x | Net Cash |
| Q1 2020 | -1.6x | Net Cash |
YCBD has more cash than debt.
YCBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
YCBD's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
YCBD PE vs Healthcare Sector
YCBD has no meaningful PE right now: it lost money over the past year.
YCBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.40 | 2.5% below |
| 20 week MA | $0.49 | 20% below |
| 50 week MA | $0.73 | 47% below |
| 100 week MA | $1.23 | 68% below |
| 200 week MA | $9.57 | 96% below |
YCBD is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
YCBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $932.4 | $1,123.2 | +20% |
| 2021 | $1,123.2 | $406.8 | -64% |
| 2022 | $406.8 | $90.0 | -78% |
| 2023 | $90.0 | $8.32 | -91% |
| 2024 | $8.32 | $3.02 | -64% |
| 2025 | $3.02 | $1.68 | -44% |
| 2026 YTD | $1.68 | $0.39 | -77% |
YCBD has finished five years in a row lower, and it's down 77% so far in 2026.